GTS Advisory Inc. is pleased to announce that it will provide co-hosting support and operational assistance as a Japan-Korea business gateway for the "Korea Deep-Tech & Bio-Health Tokyo IR Day 2026," hosted by INNOPOLIS and SYP Co., Ltd. on Thursday, October 8, 2026, in Tokyo.
This event marks the first official project in Japan since our CEO, Masahiro Kimura, assumed the role of Board Member and Senior Executive Advisor at SYP.
■ Background and Our Role
In recent years, cross-border open innovation in the deep-tech and bio-health sectors has become increasingly crucial. While South Korea possesses numerous globally competitive startups, many face challenges in finding the optimal approach and partners to enter the Japanese market.
GTS Advisory serves as a solid "gateway" connecting highly vetted Korean startups with Japanese VCs, CVCs, corporations, and local governments seeking innovative technologies and investment opportunities. We aim to build a cross-border ecosystem that contributes to the industrial development of both countries.
■ Event Overview
Five Korean startups featuring cutting-edge bio-health and medical AI technologies will visit Japan to pitch to investors and business partners.
Event Name: Korea Deep-Tech & Bio-Health Tokyo IR Day 2026
Date & Time: Thursday, October 8, 2026, 14:00-16:00
Location: Kikai Shinko Kaikan (Minato-ku, Tokyo)
Hosts: INNOPOLIS, SYP Co., Ltd.
Details & Registration: https://sypip.com/gib/#program
■ Presenting Startups & Core Technologies
MEDINNO Inc.: Focuses on "HIEstem," utilizing allogeneic umbilical cord-derived mesenchymal stem cells (MSCs) enhanced by thrombin preconditioning (MEET) to tackle intractable CNS diseases such as premature intraventricular hemorrhage (IVH) and neonatal hypoxic-ischemic encephalopathy (HIE).
Wellentech: A sleep-tech company offering a "full-cycle sleep and recovery management platform" where AI executes CBT-I (Cognitive Behavioral Therapy for Insomnia) based behavioral interventions at optimal times.
CUePEAK BIO: Provides a complex precision medicine platform for atopic dermatitis that simultaneously strengthens the skin barrier, reduces inflammation, and relieves itching. They are also rolling out functional materials like "MULTI ATO CREAM" for immediate commercialization.
Target Link Therapeutics: Developing a First-in-Class antibody and ADC platform targeting "CDH17," which is specifically exposed on the surface of gastrointestinal cancer cells.
Rewalk: Supports patients to walk safely again with "Solv," a 3-in-1 smart walking aid integrating night LEDs, heated grips, and shock absorption, reducing the risk of pressure ulcers through early mobilization care.
■ BioJapan Visit & 1-on-1 Meetings
On Wednesday, October 7, the day before the event, our CEO and SYP representatives will visit "BioJapan" at Pacifico Yokohama. We are arranging 1-on-1 meetings and networking sessions with Japanese companies at the venue. If your company is interested, please feel free to contact us.
External Article
Read related article